Treatment of capecitabine‑induced hand‑foot syndrome using a topical retinoid: A case report

Inokuchi,Masafumi; Ishikawa,Satoko; Furukawa,Hiroyuki; Takamura,Hiroyuki; Ninomiya,Itasu; Kitagawa,Hirohisa; Fushida,Sachio; Fujimura,Takashi; Ohta,Tetsuo

doi:10.3892/ol.2013.1706

Treatment of capecitabine‑induced hand‑foot syndrome using a topical retinoid: A case report

Authors:
- Masafumi Inokuchi
- Satoko Ishikawa
- Hiroyuki Furukawa
- Hiroyuki Takamura
- Itasu Ninomiya
- Hirohisa Kitagawa
- Sachio Fushida
- Takashi Fujimura
- Tetsuo Ohta
View Affiliations

Affiliations: Department of Breast Oncology, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa 920‑8641, Japan
Published online on: November 26, 2013 https://doi.org/10.3892/ol.2013.1706
Pages: 444-448

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Capecitabine is a chemotherapeutic drug used in patients with breast, colon and gastric cancer. Hand‑foot syndrome (HFS) is a type of dermatitis that frequently occurs as a reaction to capecitabine. To date, no effective strategies have been found to prevent or reverse HFS. Furthermore, chemotherapy induces an elevation in the expression of heparin‑binding epidermal growth factor‑like growth factor (HB‑EGF), and this activation represents a critical mechanism for the induction of chemotherapeutic resistance. Adapalene is a third‑generation synthetic retinoid. Topical retinoids are important therapeutic anti-aging agents for managing photodamaged skin, and are known to increase HB‑EGF levels, which is important for skin wound healing. Accordingly, the current report focused on the topical retinoids that increase HB‑EGF expression in the skin, and we hypothesized that these topical retinoids induce local chemotherapeutic resistance in the skin of patients receiving chemotherapy and consequently, decrease the cutaneous side‑effects of chemotherapy. This report presents a case of the successful treatment of refractory HFS induced by capecitabine using the topical application of adapalene. Topical adapalene was applied for 3 months and significantly reduced inflammation and pain following chemotherapy. Topical retinoids may have the potential to effectively treat capecitabine‑induced HFS by increasing HB‑EGF expression and decreasing cutaneous side‑effects. Further studies are required to establish the therapeutic efficacy of topical retinoids on HFS.

View Figures

View References

1	Shimma N, Umeda I, Arasaki M, et al: The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem. 8:1697–1706. 2000. View Article : Google Scholar : PubMed/NCBI
2	Webster-Gandy JD, How C and Harrold K: Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 11:238–246. 2007. View Article : Google Scholar
3	Lassere Y and Hoff P: Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 8(Suppl 1): S31–S40. 2004. View Article : Google Scholar : PubMed/NCBI
4	Asgari MM, Haggerty JG, McNiff JM, Milstone LM and Schwartz PM: Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutan Pathol. 26:287–294. 1999. View Article : Google Scholar
5	Mrozek-Orlowski ME, Frye DK and Sanborn HM: Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum. 26:753–762. 1999.PubMed/NCBI
6	Wang F, Liu R, Lee SW, Sloss CM, Couget J and Cusack JC: Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene. 26:2006–2016. 2007. View Article : Google Scholar
7	Piérard GE, Piérard-Franchimont C, Paquet P and Quatresooz P: Spotlight on adapalene. Expert Opin Drug Metab Toxicol. 5:1565–1575. 2009.
8	Rittié L, Varani J, Kang S, Voorhees JJ and Fisher GJ: Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 126:732–739. 2006.
9	Shirakata Y, Kimura R, Nanba D, et al: Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. J Cell Sci. 118:2363–2370. 2005. View Article : Google Scholar : PubMed/NCBI
10	Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S and Stephens R: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 8:57–63. 1990. View Article : Google Scholar
11	Yoshimoto N, Yamashita T, Fujita T, et al: Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer. 17:298–302. 2010. View Article : Google Scholar
12	Kang YK, Lee SY, Cheon YJ, et al: Pyridoxine is not effective for the prevention of capecitabine-induced hand foot syndrome (HFS): Results of a randomized double-blind placebo-controlled study. Ann Oncol. 17:286–287. 2006.
13	Kang YK, Lee SS, Yoon DH, et al: Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 28:3824–3829. 2010. View Article : Google Scholar
14	Zhang RX, Wu XJ, Wan DS, et al: Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 23:1348–1353. 2012. View Article : Google Scholar
15	Wolf SL, Qin R, Menon SP, et al; Cancer Treatment Group Study N05C5. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 28:5182–5187. 2010. View Article : Google Scholar
16	Darlenski R, Surber C and Fluhr JW: Topical retinoids in the management of photodamaged skin: from theory to evidence-based practical approach. Br J Dermatol. 163:1157–1165. 2010. View Article : Google Scholar : PubMed/NCBI
17	Suganuma K, Kubota T, Saikawa Y, et al: Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci. 94:355–359. 2003. View Article : Google Scholar
18	DeWitt CA, Siroy AE and Stone SP: Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol. 56:500–505. 2007. View Article : Google Scholar : PubMed/NCBI
19	Hachisuka J, Doi K, Moroi Y and Furue M: Successful treatment of epidermal growth factor receptor inhibitor-induced periungual inflammation with adapalene. Case Rep Dermatol. 3:130–136. 2011. View Article : Google Scholar
20	Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355:2733–2743. 2006. View Article : Google Scholar
21	Fuchs E and Raghavan S: Getting under the skin of epidermal morphogenesis. Nat Rev Genet. 3:199–209. 2002. View Article : Google Scholar : PubMed/NCBI
22	Mukherjee S, Date A, Patravale V, Korting HC, Roeder A and Weindl G: Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 1:327–348. 2006. View Article : Google Scholar : PubMed/NCBI
23	Segaert S and Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 16:1425–1433. 2005. View Article : Google Scholar
24	Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 6:803–812. 2006. View Article : Google Scholar : PubMed/NCBI